This double-blind, randomized phase II trial evaluated regorafenib versus placebo in pretreated biliary tract cancer patients.
Regorafenib significantly increased mPFS versus placebo, from 1.5 to 3.0 months ( P = 0.004).
Regorafenib significantly increased tumor control.
There were no new or unexpected safety signals.
There is a high unmet clinical need for treatments of advanced/metastatic biliary tract cancers after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress on standard therapies.
Patients and methods
REACHIN was a multicenter, double-blind, placebo-controlled, randomized phase II study designed to evaluate the safety and efficacy of regorafenib in patients with nonresectable/metastatic biliary tract cancer that progressed after gemcitabine/platinum chemotherapy. Patients were randomly assigned 1 : 1 to best supportive care plus either regorafenib 160 mg once daily 3 weeks on/1 week off or placebo until progression or unacceptable toxicity. No crossover was allowed. The primary objective was progression-free survival (PFS). Secondary objectives were response rate, overall survival, and translational analysis.
Sixty-six patients with intrahepatic ( n = 42), perihilar ( n = 6), or extrahepatic ( n = 9) cholangiocarcinoma, or gallbladder carcinoma ( n = 9) were randomized, 33 to each treatment group (33 per group). At a median follow-up of 24 months, all patients had progressed and six patients were alive. Median treatment duration was 11.0 weeks [95% confidence interval (CI): 6.0–15.9] in the regorafenib group and 6.3 weeks (95% CI: 3.9–7.0) in the placebo group ( P = 0.002). Fourteen of 33 patients (42%) in the regorafenib group had a dose reduction. Stable disease rates were 74% (95% CI: 59–90) in the regorafenib group and 34% with placebo (95% CI: 18–51; P = 0.002). Median PFS in the regorafenib group was 3.0 months (95% CI: 2.3–4.9) and 1.5 months (95% CI: 1.2–2.0) in the placebo group (hazard ratio 0.49; 95% CI: 0.29–0.81; P = 0.004) and median overall survival was 5.3 months (95% CI: 2.7–10.5) and 5.1 months (95% CI: 3.0–6.4), respectively ( P = 0.28). There were no unexpected/new safety signals.
Regorafenib significantly improved PFS and tumor control in patients with previously treated metastatic/unresectable biliary tract cancer in the second- or third-line setting.
Clinical Trial Registration
To read this article in full you will need to make a payment
- Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study.JAMA Oncol. 2018; 4: 1553-1568
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.Lancet Oncol. 2019; 20: 663-673
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2016; 27: v28-v37
- Hepatobiliary Cancers, Version 1.2019.(Available at)https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary_blocks.pdfDate accessed: January 28, 2019
- Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med. 2010; 362: 1273-1281
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet. 2013; 381: 303-312
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, prospective, placebo-controlled, phase 3 trial.Lancet. 2013; 381: 295-302
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 389: 56-66
- BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res. 2004; 64: 7099-7109
- Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.Int J Cancer. 2011; 129: 245-255
- Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.Mol Cancer Ther. 2013; 12: 1322-1331
- Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.Gut. 2003; 52: 706-712
- Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma.Curr Opin Gastroenterol. 2011; 27: 276-284
- The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of ‘scirrhous-type’ and ‘nonscirrhous-type’ growth.Am J Surg Pathol. 1999; 23: 892-902
- Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.Biochem Pharmacol. 2007; 73: 1308-1317
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.Br J Cancer. 2010; 102: 68-72
- SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.Invest New Drugs. 2012; 30: 1646-1651
- Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.Oncotarget. 2017; 8: 107096-107108
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.Cancer. 2019; 125: 902-909
- Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.J Clin Oncol. 2018; 36 (abstract 4082)
- Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.Lancet Oncol. 2019; 20: 1070-1082
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomized phase 2 trial.Lancet Oncol. 2015; 16: 967-978
- A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.Oncol Lett. 2017; 13: 2957-2964
- Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.Oncotarget. 2017; 8: 17246-17257
- A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.Cancer. 2017; 123: 1979-1988
- Genomic spectra of biliary tract cancer.Nat Genet. 2015; 47: 1003-1010
- Molecular genomic landscapes of hepatobiliary cancer.Cancer Sci. 2018; 109: 1282-1291
- Fibroblast-growth factor receptor 2 translocations in intra-hepatic cholangiocarcinoma.Hum Pathol. 2014; 45: 1630-1638
- ABC-06 A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.J Clin Oncol. 2019; 37 (abstract 4003)
- Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).J Clin Oncol. 2019; 37: 2522
Published online: May 24, 2020
© 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.